17159-80-7

Basic information

• Product Name: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE
• Synonyms: Ethyl 4-hydroxycyclohexanecarboxylate, mixture of cis and trans ,98%;ethyl 4-hydroxycyclohexane-1-carboxylate;Ethyl 4-hydroxycyclohexylcarboxylate;Ethyl 4-hydroxycyclohexanecarboxylate, Mixture of cis and trans 98%;Ethyl 4-hydroxycyclohexanecarbonate;Ethyl 4-hydroxycyclohexanecarboxylate≥ 99% (assay);ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE;Ethyl 4-hydroxycyclohexanecarboxylate,mixture of cis and trans
• CAS NO: 17159-80-7
• Molecular Formula: C₉H₁₆O₃
• Molecular Weight: 172.22
• EINECS: 241-215-1
• Product Categories: C8 to C9;Carbonyl Compounds;Esters
• Mol File: 17159-80-7.mol

Chemical Properties

• Boiling Point: 127-134 °C0.1 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.068 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00322mmHg at 25°C
• Refractive Index: n20/D 1.466(lit.)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 14.98±0.40(Predicted)
• Water Solubility: Not miscible or difficult to mix in water.
• CAS DataBase Reference: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE(17159-80-7)
• EPA Substance Registry System: ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE(17159-80-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 17159-80-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE is used as a chemical intermediate for the synthesis of other chemicals. It plays a vital role in the production of various compounds due to its reactive functional groups and compatibility with a wide range of chemical reactions.
Used in Pharmaceutical Industry:
ETHYL 4-HYDROXYCYCLOHEXANECARBOXYLATE is used as a pharmaceutical intermediate for the development of new drugs and medications. Its unique structure and reactivity make it an essential component in the synthesis of various pharmaceutical compounds, contributing to the advancement of medical treatments and therapies.

Synthesis Reference(s)

The Journal of Organic Chemistry, 30, p. 4145, 1965 DOI: 10.1021/jo01023a039

InChI:InChI=1/C9H16O3/c1-2-12-9(11)7-3-5-8(10)6-4-7/h7-8,10H,2-6H2,1H3

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 123-91-1 1,4-dioxane 
• 99-96-7 4-hydroxy-benzoic acid 
• 64-17-5 ethanol 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 

Downstream Products

• 53287-45-9 4-chloro-1-cyclohexanecarboxylic acid chloride 
• 676560-15-9 Ethyl (cis/trans)-4-<(tert-butyldimethylsilyl)oxy>cyclohexanecarboxylate 
• 223699-80-7 cis-pentamethylbenzyl 4-hydroxycyclohexanecarboxylate 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 923-42-2 butane-1,2,4-tricarboxylic acid 
• 17419-82-8 cis/trans-4-hydroxy-cyclohexanecarboxylic acid hydrazide 
• 15580-01-5 4-Hydroxy-1-acetyl-cyclohexan 
• 651735-13-6 ethyl-4-[3-(2,6-difluoro-3,5-dimethoxy-phenyl)-7-methylsulfanyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-cyclohexanecarboxylate 
• 238400-51-6 4-methoxybenzyl 4-hydroxycyclohexanoate 
• 913573-70-3 ethyl 4-[({[1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-yl]amino}carbonyl)oxy]cyclohexanecarboxylate 
• 948555-94-0 ethyl 4-(4-bromophenoxy)cyclohexanecarboxylate 
• 1227188-04-6 cis/trans-4-(methylthiocarbonothioyloxy)cyclohexanecarboxylic acid ethyl ester 
• 1415573-45-3 cis-ethyl 4-(pyridin-4-yloxy)cyclohexanecarboxylate 
• 1415573-46-4 trans-ethyl 4-(pyridin-4-yloxy)cyclohexanecarboxylate 

Relevant articles and documents

A scalable synthesis of a 1,7-naphthyridine derivative, a PDE-4 inhibitor

A six-step synthesis of a 4-[8-(3-fluorophenyl)[1,7]naphthyridin-6-yl]- trans-cyclohexanecarboxylic acid with an overall yield of 27% starting from 2-cyano-3-methylpyridine, cyclohexane-1,4-dicarboxylic acid dimethyl ester, and 3-fluorophenylboronic acid is described. The trans stereochemistry in the cyclohexane moiety was achieved through a series of equilibration steps at different stages of the synthesis.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.; Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163).

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

A biocatalytic/reductive etherification approach to substituted piperidinyl ethers

A synthetically useful protocol has been developed for the preparation of highly functionalized piperidinyl ethers. Biocatalytic reduction of cyclhexanones 7, 10, and 14 allows for the preparation of both cis- and trans diastereomers with an extremely high degree of stereochemical control. Reductive etherification of the corresponding trimethylsilylethers with 1-(benzyloxycarbonyl)-4-piperidinone 17 in the presence of triethylsilane and catalytic TMSO-Tf provides the desired piperidinyl ethers in good to excellent yields. Finally hygrogenolysis of the nitrogen protecting group leads to piperidinyl ethers in near quantitative yields. Application of the methodology to a range of piperidinyl ethers, including the core scaffolds of diphenylpyraline and ebastine, is also described.

IMIDAZOLE DERIVATIVES

Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY

2,4-Diaminoquinazolines of formula (I) are provided herein and are useful for treating spinal muscular atrophy (SMA).

THERAPEUTIC AMIDE DERIVATIVES

The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: A and B independently represent CH2 or O, with the proviso that A and B are not simultaneously O; Cy represents one of the following Formula (II) optionally substituted by one to three groups selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy, C1-6 haloalkyl, C1-6alkylamino and amino; R1 and R2 are independently selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy, C1-6 haloalkyl and C3-8 cycloalkyl; n represents an integer from 0-4; X is hydrogen, hydroxy, halogen or C1-6alkoxy; Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy and C1-6 haloalkyl; Z is CH or N; and p represents an integer from 0-5 when Z is CH or 0-4 when Z is N; when p represents 2 or more, two of R2s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.

4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.

Selective reductions with stable indium trihydride reagents

The carbene and tertiary phosphine adducts of indane, [InH3{CN(Mes)C2H2N(Mes)}] and [InH3{P(C6H11)3}] (Mes = 2,4,6-trimethylphenyl), have been used to reduce unsaturated organic functionalities. The success and selectivity of these reductions relative to those carried out with lighter group 13 hydride complexes is discussed. (C) 2000 Elsevier Science Ltd.